- Home
- ZYME vs NX Comparison
ZYME vs NX Comparison
Compare ZYME & NX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZYME
- NX
- Stock Information
- Founded
- ZYME 2003
- NX 1927
- Country
- ZYME United States
- NX United States
- Employees
- ZYME N/A
- NX N/A
- Industry
- ZYME Biotechnology: Pharmaceutical Preparations
- NX Metal Fabrications
- Sector
- ZYME Health Care
- NX Industrials
- Exchange
- ZYME Nasdaq
- NX Nasdaq
- Market Cap
- ZYME 983.6M
- NX 1.1B
- IPO Year
- ZYME 2017
- NX N/A
- Fundamental
- Price
- ZYME $11.62
- NX $18.30
- Analyst Decision
- ZYME Buy
- NX Strong Buy
- Analyst Count
- ZYME 6
- NX 1
- Target Price
- ZYME $19.50
- NX $38.00
- AVG Volume (30 Days)
- ZYME 718.6K
- NX 598.6K
- Earning Date
- ZYME 05-01-2025
- NX 03-10-2025
- Dividend Yield
- ZYME N/A
- NX 1.72%
- EPS Growth
- ZYME N/A
- NX N/A
- EPS
- ZYME N/A
- NX 0.29
- Revenue
- ZYME $76,304,000.00
- NX $1,438,751,000.00
- Revenue This Year
- ZYME $26.29
- NX $48.92
- Revenue Next Year
- ZYME $75.78
- NX $3.10
- P/E Ratio
- ZYME N/A
- NX $64.00
- Revenue Growth
- ZYME 0.38
- NX 29.87
- 52 Week Low
- ZYME $7.97
- NX $18.14
- 52 Week High
- ZYME $17.70
- NX $38.98
- Technical
- Relative Strength Index (RSI)
- ZYME 37.79
- NX 35.35
- Support Level
- ZYME $12.15
- NX $19.53
- Resistance Level
- ZYME $13.28
- NX $20.47
- Average True Range (ATR)
- ZYME 0.59
- NX 0.68
- MACD
- ZYME -0.02
- NX -0.05
- Stochastic Oscillator
- ZYME 7.33
- NX 6.15
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated product candidates. Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
About NX Quanex Building Products Corporation
Quanex Building Products Corp is a manufacturer of components sold to original equipment manufacturers in the building products industry. It manufactures engineered products like window and door components that include flexible insulating glass spacers, extruded vinyl profiles, window and door screens, solar panel sealants and precision-formed metal and wood products among others. Its three operating segments are North American Fenestration being the key revenue driver, European Fenestration, and North American Cabinet Components. Geographically, it derives a majority of revenue from the United States.